

宏利盈進基金 SPC (「本公司」)

P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands

此乃重要文件，務請閣下立即垂注。閣下如有任何疑問，應徵詢獨立法律、財務或其他專業意見。本公司董事對本通知書所載資料的準確性承擔全部責任，並經一切合理查詢後確認，盡其所知所信，並無遺漏足以令其任何陳述具誤導成分的其他事實。

除非另有指明，否則本通知書中所使用的詞語及字句的涵義與本公司日期為 2021 年 3 月的售股章程（「售股章程」）中所賦予者相同。

致股東通知書

2021 年 12 月 13 日

親愛的股東：

我們謹此通知閣下現正對本公司及人民幣債券獨立資產組合（「債券基金」）作出的若干更改。

A. 債券基金的投資策略之更改

目前，債券基金並無對具吸收虧損特點的債務工具（「LAP」）作出任何投資。為了在管理債券基金風險及回報狀況時擁有更大靈活性，由 2022 年 1 月 17 日（「生效日期」）起，債券基金的投資策略將作出修訂，以訂明債券基金可將其最多 20% 的淨資產投於 LAP，包括但不限於具完全吸收虧損能力的合資格工具、或然可換股債務證券、某些類型的高級非優先債務，以及具與發行機構監管資本比率相關之減記或內部債務重整特性的其他類似工具（「LAP 更改」）。

目前，債券基金只可為對沖目的而取得金融衍生工具。為了在債券基金挑選投資時擁有更大靈活性，以更能達致其投資目標，由生效日期起，債券基金使用衍生工具之目的將擴大，以至債券基金可為對沖及投資目的而取得金融衍生工具。

上述更改並不對債券基金構成重大變更。經作出 LAP 更改後，債券基金將承受與投資於 LAP 相關的額外風險，但債券基金的整體風險狀況將不會出現重大改變或增加。儘管債券基金使用衍生工具之目的擴大，惟債券基金的衍生工具風險承擔淨額維持最高可達債券基金最近可得資產淨值的 50%。該等更改並不對股東的權利或權益構成重大不利影響（包括可能限制股東行使其權利的能力之變動）。

B. 宏利投資管理（香港）有限公司地址的更改

由 2021 年 9 月 20 日起，宏利投資管理（香港）有限公司的地址已更改為「香港特別行政區銅鑼灣希慎道 33 號利園一期 10 樓」。

C. 可供索取文件

售股章程及債券基金的產品資料概要（「產品資料概要」）將作出更新，以反映債券基金上述的更改，包括加強與投資於 LAP 相關的風險披露，以及其他相關更新。售股章程亦將作出更新，以反映宏利投資管理（香港）有限公司地址的更改。

經修訂售股章程及債券基金的產品資料概要的副本將於生效日期當日或前後的正常辦公時間在總顧問及下列分銷商的辦事處，以及在投資管理人的網站可供免費查閱，網址為<http://www.manulifefunds.com.hk>¹。有關進一步詳情，請參閱經修訂售股章程及債券基金的產品資料概要。

D. 查詢

股東如需要關於本通知書所載事項的進一步資料，可於相關地區當地的正常營業時間內隨時聯絡分執行人Citibank Europe plc, Luxembourg Branch，電話(352) 45 14 14 316或傳真(352) 45 14 14 850，或聯絡總顧問及分銷商宏利投資管理（香港）有限公司，地址為香港特別行政區銅鑼灣希慎道33號利園一期10樓，或電話(852) 2108 1110或傳真(852) 2810 9510（關於AA類股份），或電話(852) 2510 3055或傳真(852) 2907 2076（關於C類、D類、I類及P類股份）。

代表
宏利盈進基金SPC
董事會

¹ 此網站未經證監會審閱。

Manulife Advanced Fund SPC (the “Company”)

P.O. Box 309, Uglan House, Grand Cayman, KY1-1104, Cayman Islands

This document is important and requires your immediate attention. If in doubt, you should seek independent legal, financial or other professional advice. The Directors of the Company accept full responsibility for the accuracy of the information contained in this Notice and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief there are no other facts the omission of which would make any statement misleading.

Words and phrases used in this Notice shall, unless otherwise provided, have the same meanings as ascribed to them in the Prospectus of the Company dated March 2021 (the “Prospectus”).

NOTICE TO SHAREHOLDERS

13 December 2021

Dear Shareholder,

We are writing to inform you of certain changes we are making to the Company and the Renminbi Bond Segregated Portfolio (the “**Bond Fund**”).

A. Change to the investment strategy of the Bond Fund

Currently, the Bond Fund does not make any investment in debt instruments with loss-absorption features (“**LAP**”). To allow greater flexibility in managing the Bond Fund’s risk and return profiles, with effect from 17 January 2022 (the “**Effective Date**”), the investment strategy of the Bond Fund will be amended to provide that the Bond Fund may invest up to 20% of net assets in LAP including, but not limited to, total loss-absorbing capacity eligible instruments, contingent convertible debt securities, certain types of senior non-preferred debt, and other similar instruments with write-down or bail-in features related to the issuers’ regulatory capital ratio (the “**LAP Change**”).

Currently, the Bond Fund may acquire financial derivative instruments for hedging purposes only. To allow greater flexibility in the investment selection of the Bond Fund to better achieve its investment objective, with effect from the Effective Date, the purpose of use of derivatives of the Bond Fund will be expanded such that the Bond Fund may acquire financial derivative instruments for hedging and investment purposes.

The above changes do not amount to a material change to the Bond Fund. Following the LAP Change, the Bond Fund will be subject to additional risks associated with investment in LAP, but there will be no material change or increase in the overall risk profile of the Bond Fund. Notwithstanding the expansion of the purpose of use of derivatives of the Bond Fund, the net derivative exposure of the Bond Fund remains to be up to 50% of the Bond Fund’s latest available Net Asset Value. The changes do not have a material adverse impact on Shareholders’ rights or interests (including changes that may limit Shareholders’ ability in exercising their rights).

B. Change of Address of Manulife Investment Management (Hong Kong) Limited

With effect from 20 September 2021, the address of Manulife Investment Management (Hong Kong) Limited is changed to “10th Floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong SAR”.

C. Availability of Documents

The Prospectus and the product key facts statement (“KFS”) of the Bond Fund will be updated to reflect the above changes to the Bond Fund, including enhancement of risk disclosures associated with investments in LAP, and other related updates. The Prospectus will also be updated to reflect the change of address of Manulife Investment Management (Hong Kong) Limited.

A copy of the revised Prospectus and the KFS of the Bond Fund will be available for inspection, free of charge, at the office of the General Adviser and Distributor stated below during normal working hours, and on the website of the Investment Manager at <http://www.manulifefunds.com.hk>¹ on or around the Effective Date. Please refer to the revised Prospectus and the KFS of the Bond Fund for further details.

D. Enquiries

Shareholders requiring further information about the matters set out in this Notice may contact the Sub-Administrator, Citibank Europe plc, Luxembourg Branch on telephone number (352) 45 14 14 316 or fax number (352) 45 14 14 850, or the General Adviser and Distributor, Manulife Investment Management (Hong Kong) Limited, at 10th Floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong SAR, or on telephone number (852) 2108 1110 or fax number (852) 2810 9510 (relating to Class AA Shares), or telephone number (852) 2510 3055 or fax number (852) 2907 2076 (relating to Class C, Class D, Class I and Class P Shares) at any time during normal local business hours.

**For and on behalf of the Board
Manulife Advanced Fund SPC**

¹ This website has not been reviewed by the SFC.